Home›Trial›NCT05702034

🔬NCT05702034Phase 3RECRUITING

A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

Study Summary

The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.

Conditions

Ischemic Stroke; Ischemic Attack, Transient

Interventions / Drugs

Milvexian Placebo

View on ClinicalTrials.gov ↗

Sponsor

Johnson & Johnson

Diversified Pharma

Study Details

Enrollment15000 participants

Primary Completion—

Lead SponsorJanssen Research & Development, LLC

Data Retrieved2026-04-11 02:55:31.550787+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.